Firefly Luciferase CD19 Knockout Raji Cell Line

Catalog #

82167

$5,200 *

Size: 2 vials

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Firefly Luciferase CD19 Knockout Raji Cell Line is a Raji cell line constitutively expressing firefly (Photinus pyralis) luciferase under the control of a CMV promoter, where CD19 (Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) has been genetically removed using CRISPR/Cas9 genome editing. This cell line was generated by using Firefly Luciferase Lentivirus (BPS Bioscience #79692) on CD19 Knockout Raji Cell Line (BPS Bioscience #82166).

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

●

Product Data Gallery

Genomic sequencing of CD19 in the Firefly Luciferase CD19 Knockout Raji Cell Line

CD19 Expression in Firefly Luciferase CD19 Knockout Raji Cell Line.

Luciferase activity in Firefly Luciferase CD19 Knockout Raji Cell Line.

Product Info

Storage and Usage

Citations

Host Cell Line

Raji human B lymphoblastoid cell line, derived from a patient with Burkitt lymphoma. Suspension cells.

Supplied As

Each vial contains ˃1 x 10⁶ cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)

Materials Required But Not Supplied

Materials Required for Cell Line Culture

Name	Ordering Information
Thaw Medium 2	BPS Bioscience #60184
Growth Medium 2E	BPS Bioscience #79638

Materials Used in Cellular Assay

Name	Ordering Information
Thaw Medium 2	BPS Bioscience #60184
Growth Medium 2E	BPS Bioscience #79638
Anti-CD19 Antibody, PE-Labeled	BPS Bioscience #101625
96-well Tissue Culture-treated White Clear-bottom Assay plate	Corning #3610
ONE-Step™ Luciferase Assay System	BPS Bioscience #60690
Luminometer

Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

The Raji line was established from a Burkitt's lymphoma patient. Raji cells constitutively express B cell antigens CD19, CD20, and CD22, and offer a physiologically relevant platform to evaluate cancer-directed immunotherapies such as Chimeric Antigen Receptor (CAR) T-cells. The signal generated by the firefly luciferase reporter is proportional to Raji cell numbers and facilitates the quantification of Raji cell killing upon co-culture with CAR-T or NK cells.

CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production, such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.

Storage/Stability

Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at [email protected] if the cells are not frozen in dry ice upon arrival.

Growth Media

For best results, the use of validated and optimized media from BPS Bioscience is highly recommended. Other preparations or formulations of media may result in suboptimal performance.

Thaw Medium 2 (BPS Bioscience #60184): RPMI 1640 medium supplemented with 10% FBS and 1% Penicillin/Streptomycin.

Growth Medium 2E (BPS Bioscience #79638): RPMI 1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 0.5 µg/ml of Puromycin Dihydrochloride.

Applications

Use as a control in CAR-T or NK co-culture killing assays
In vitro and in vivo bioluminescence imaging

Shipping Temperature

-80°C

Notes

The CRISPR/CAS9 technology is covered under numerous patents, including U.S. Patent Nos. 8,697,359 and 8,771,945, as well as corresponding foreign patents applications, and patent rights.

License Disclosure
Visit bpsbioscience.com/license for the label license and other key information about this product.

Troubleshooting Guide
Visit bpsbioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email [email protected].

Warnings

Avoid freeze/thaw cycle

Scientific Category

Cancer Therapy Target

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Firefly Luciferase CD19 Knockout Raji Cell Line

PRODUCTS

SERVICES

RESOURCES

COMPANY